Kisspeptin treatment induces gonadotropic responses and rescues ovulation in a subset of preclinical models and women with polycystic ovary syndrome

What Was Tested

The paper reports a study of Kisspeptin-10, published as a clinical trial.

Can kisspeptin treatment induce gonadotrophin responses and ovulation in preclinical models and anovulatory women with polycystic ovary syndrome (PCOS)?

Kisspeptins (encoded by Kiss1) are master regulators of the reproductive axis, acting mainly at GnRH neurons, with kisspeptins being an essential drive for gonadotrophin-driven ovarian follicular maturation and ovulation.

Who Took Part

By PubMed's age tags, the people studied were young adults and adults, women only.

Gonadotrophin and ovarian/ovulatory responses to kisspeptin-54 (KP-54) were evaluated in three preclinical models of PCOS, generated by androgen exposures at different developmental windows, and a pilot exploratory cohort of anovulatory women with PCOS.

Three models of PCOS were generated by exposure of female rats to androgens at different periods of development: PNA (prenatal androgenization; N = 20), NeNA (neonatal androgenization; N = 20) and PWA (post-weaning androgenization; N = 20).

How the Study Was Run

The researchers set it up as a pilot study.

It is described as a pilot, a small early test of whether a larger Kisspeptin-10 study would be practical.

On Days 1, 4, 7 and 11, LH and FSH responses were assessed at different time-points within 4 h after KP-54 injection, while ovarian responses, in terms of follicular maturation and ovulation, were measured at the end of the treatment.

What Was Measured

PubMed files the paper under topics including Disease Models, Animal, Follicle Stimulating Hormone, Kisspeptins, Luteinizing Hormone, Ovulation, Pilot Projects and Polycystic Ovary Syndrome.

The authors tagged it with the keywords gonadotrophins, ovarian stimulation and preclinical models.

What This Means in Plain Language

The paper is a pilot study of Kisspeptin-10.

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2019 (Human reproduction (Oxford, England)), a journal based in England.

More context: the Kisspeptin-10 compound page, all human trials.